Roivant Sciences (ROIV) Aandelenoverzicht
Roivant Sciences Ltd., een biofarmaceutisch bedrijf in een klinische fase, richt zich op het ontdekken, ontwikkelen en commercialiseren van medicijnen en technologieën. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 2/6 |
| Toekomstige groei | 2/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 6/6 |
| Dividenden | 0/6 |
ROIV Community Fair Values
Create NarrativeSee what 17 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Roivant Sciences Ltd. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$35.13 |
| 52 Week Hoogtepunt | US$35.90 |
| 52 Week Laag | US$10.71 |
| Bèta | 1.11 |
| 1 maand verandering | 22.92% |
| 3 maanden verandering | 26.00% |
| 1 Jaar Verandering | 219.65% |
| 3 jaar verandering | 225.28% |
| 5 jaar verandering | 254.85% |
| Verandering sinds IPO | 237.79% |
Recent nieuws en updates
Narratiefupdate • Jun 22
ROIV: 2026 Autoimmune Readouts And Regulatory Milestones Will Drive Repricing
Analysts have raised their average price target on Roivant Sciences to $39.04, citing updated models following recent earnings, pipeline data, and revised assumptions regarding the discount rate, profit margin, and forward P/E. Analyst Commentary Recent research updates on Roivant Sciences point to a more constructive stance from several firms, with higher price targets tied to refreshed models following quarterly results, pipeline data and changes to key assumptions such as discount rates, profit margins and forward P/E multiples.Analyseartikel • Jun 19
Roivant Sciences (ROIV) Stock Could Be 19.5% Undervalued After Moderna Settlement And Pipeline Progress
Roivant Sciences (ROIV) has drawn fresh attention after announcing a US$2.25b global settlement with Moderna that ends ongoing patent litigation, along with positive IMVT-1402 rheumatoid arthritis data and Breakthrough Therapy Designation for brepocitinib. See our latest analysis for Roivant Sciences. At a share price of US$31.43, Roivant Sciences has seen a 4.63% 7 day share price return and a 13.47% 90 day share price return. Its 1 year total shareholder return of 174.50% and 3 year total...Narratiefupdate • Jun 06
ROIV: 2026 Autoimmune Readouts And Breakthrough Status Will Drive Repricing
Roivant Sciences' updated analyst price target, which rises from $35.71 to $39.04, reflects analysts' refreshed models following recent earnings, pipeline updates, and data from IMVT-1402 that they view as supportive of the stock's risk and reward profile. Analyst Commentary Street research on Roivant Sciences has recently leaned constructive, with several major firms updating models and adjusting valuation targets after the latest earnings reports and IMVT-1402 data.Recent updates
Narratiefupdate • Jun 22
ROIV: 2026 Autoimmune Readouts And Regulatory Milestones Will Drive Repricing
Analysts have raised their average price target on Roivant Sciences to $39.04, citing updated models following recent earnings, pipeline data, and revised assumptions regarding the discount rate, profit margin, and forward P/E. Analyst Commentary Recent research updates on Roivant Sciences point to a more constructive stance from several firms, with higher price targets tied to refreshed models following quarterly results, pipeline data and changes to key assumptions such as discount rates, profit margins and forward P/E multiples.Analyseartikel • Jun 19
Roivant Sciences (ROIV) Stock Could Be 19.5% Undervalued After Moderna Settlement And Pipeline Progress
Roivant Sciences (ROIV) has drawn fresh attention after announcing a US$2.25b global settlement with Moderna that ends ongoing patent litigation, along with positive IMVT-1402 rheumatoid arthritis data and Breakthrough Therapy Designation for brepocitinib. See our latest analysis for Roivant Sciences. At a share price of US$31.43, Roivant Sciences has seen a 4.63% 7 day share price return and a 13.47% 90 day share price return. Its 1 year total shareholder return of 174.50% and 3 year total...Narratiefupdate • Jun 06
ROIV: 2026 Autoimmune Readouts And Breakthrough Status Will Drive Repricing
Roivant Sciences' updated analyst price target, which rises from $35.71 to $39.04, reflects analysts' refreshed models following recent earnings, pipeline updates, and data from IMVT-1402 that they view as supportive of the stock's risk and reward profile. Analyst Commentary Street research on Roivant Sciences has recently leaned constructive, with several major firms updating models and adjusting valuation targets after the latest earnings reports and IMVT-1402 data.Seeking Alpha • May 21
Roivant: Immunovant's Rheumatoid Arthritis Win Validates The Buy
Summary Roivant (ROIV) remains a Buy as its unique 'vant' structure rapidly advances and monetizes blockbuster assets, notably through Immunovant’s IMVT-1402 in rheumatoid arthritis. IMVT-1402 delivered strong Phase 2 efficacy in difficult-to-treat rheumatoid arthritis, with ACR20/50/70 rates of 72.7%, 54.5%, and 35.8%, respectively. ROIV’s financial position is robust, ending the quarter with $4.3 billion in cash and a management-asserted runway to profitability. Risks include late-stage trial failure, competition, regulatory setbacks, pricing pressure, premium valuation, and complexity in valuing the parent across its 'vants.' Read the full article on Seeking AlphaNarratiefupdate • May 19
ROIV: Settlement Windfall Will Shift Focus Toward 2026 Clinical Readouts
Analysts have increased their average price target on Roivant Sciences by about $0.04 to $35.71, citing updated models that factor in litigation settlement proceeds, the brepocitinib priority review and a lower assumed discount rate, along with adjusted profit margin and future P/E assumptions. Analyst Commentary Recent research updates on Roivant Sciences show a mix of optimism around litigation proceeds and key pipeline milestones, alongside some caution around how much of this is already reflected in current valuations.Narratiefupdate • Apr 21
ROIV: Settlement Cash Will Shift Focus Toward 2026 Late Stage Readouts
The updated analyst price target for Roivant Sciences moves from $33.25 to about $35.67, with analysts pointing to revised models that incorporate the Moderna settlement proceeds, a slightly higher assumed discount rate, modest tweaks to long term profit margin expectations, and a higher future P/E multiple. Analyst Commentary Recent research updates focus heavily on the impact of the Moderna settlement, how the proceeds flow through Roivant Sciences' financial model, and what that might mean for valuation versus execution risk.Narratiefupdate • Apr 05
ROIV: Settlement Cash Will Refocus Story On 2026 Clinical Readouts
Analysts have nudged their average price target for Roivant Sciences to $33, reflecting updated models that factor in the $2.25b litigation settlement with Moderna and the removal of what several firms describe as a major overhang on the story. Analyst Commentary Street research on Roivant Sciences has clustered around two core themes: the impact of the US$2.25b litigation settlement and what that means for valuation, and the shift in focus toward the company’s clinical and execution milestones.Narratiefupdate • Mar 22
ROIV: Moderna Settlement Cash Sets Up 2026 Clinical Readout Repricing
Narrative Update on Roivant Sciences The analyst price target for Roivant Sciences has been adjusted from $32.27 to $33.25. Analysts cite the Moderna litigation settlement, related $2.25b proceeds, and the removal of a major overhang as key supports for their updated models.Narratiefupdate • Mar 07
ROIV: Moderna Settlement Clears Path For 2026 Clinical Readout Upside
Analysts have nudged their average price target for Roivant Sciences higher to about $32, supported by updated models that factor in the $2.25b Moderna settlement. They view the resolution of the litigation as lifting a major overhang and refocusing attention on upcoming clinical readouts.Narratiefupdate • Feb 21
ROIV: 2026 Clinical Readouts Are Expected To Unlock Further Upside
Roivant Sciences' analyst price target has increased from $27.00 to about $31.73 as analysts factor in updated assumptions around revenue growth, margin potential and a lower future P/E based on recent Street research. Analyst Commentary Recent Street research shows a cluster of price target increases for Roivant Sciences, with several firms revisiting their models around revenue potential, profitability and valuation multiples.Narratiefupdate • Feb 06
ROIV: 2026 Trial Results And IP Litigation Are Expected To Unlock Upside
Narrative Update Analysts have lifted their blended price target on Roivant Sciences by US$3, citing recent Street research that points to ongoing batoclimab Phase 3 trial progress, a clearer 2026 data timeline, and Roivant's position in the royalty dispute backdrop with Moderna. Analyst Commentary Street research on Roivant Sciences is generally constructive, with recent notes focusing on valuation support from batoclimab, the timing of key Phase 3 readouts, and the ongoing royalty dispute backdrop with Moderna.Narratiefupdate • Jan 22
ROIV: 2026 Trial Readouts And IP Litigation Are Expected To Drive Upside
Narrative Update: Roivant Sciences (ROIV) Analysts have modestly raised their average price target on Roivant Sciences to about $27, citing updated assumptions around batoclimab trial timelines into 2026 and Roivant's role in ongoing Moderna IP litigation as key factors behind the revised outlook. Analyst Commentary Recent research points to a mixed but generally constructive view on Roivant Sciences, with attention on batoclimab timing and the evolving relationship with Moderna as key inputs into valuation and execution risk.Narratiefupdate • Jan 08
ROIV: 2026 Clinical Readouts And LNP Litigation Are Expected To Drive Upside
Analysts have lifted their price expectations for Roivant Sciences, with the blended fair value estimate moving from US$25.64 to about US$27.00 as they weigh updated Phase 3 timelines, a slightly lower discount rate, and higher assumed future P/E multiples, alongside perceived improvements in counter-party credit quality related to ongoing IP litigation. Analyst Commentary Recent Street research on Roivant Sciences reflects a mix of optimism around the pipeline and valuation support, alongside some caution on execution timing and external legal factors.Narratiefupdate • Dec 15
ROIV: Late Stage Pipeline And LNP Litigation Will Drive Upside Into 2026
Analysts have nudged their blended fair value estimate for Roivant Sciences higher, lifting the implied price target by about $1 to approximately $25.64. They are factoring in a richer future earnings multiple and growing confidence in the company’s late stage pipeline and ongoing litigation optionality, despite slightly softer margin and growth assumptions.Narratiefupdate • Nov 30
ROIV: Positive Phase 3 Data Will Drive Shares Into 2026 And Beyond
The analyst price target for Roivant Sciences has increased from approximately $23.27 to $24.55. Analysts cite stronger revenue growth forecasts and recent positive clinical trial updates as factors driving an improved company outlook.Narratiefupdate • Nov 16
ROIV: Upcoming Data From Phase 3 Trials Will Drive Shares Higher
Analysts have raised their fair value estimate for Roivant Sciences from $20.86 to $23.27 per share. They cite strong Phase 3 trial results, continued clinical progress, and anticipated upcoming catalysts as key factors behind the updated price target.Narratiefupdate • Oct 31
ROIV: Positive Phase 3 Results And Legal Uncertainty Will Shape Medium-Term Outlook
The analyst price target for Roivant Sciences has been increased by approximately $0.82 to $20.86 per share. Analysts cite strong Phase 3 trial results and a positive outlook for brepocitinib as key drivers of their upward revisions.Narratiefupdate • Oct 17
Late-stage Trials For Brepocitinib And Batoclimab Will Unlock Potential, But Execution Risks Remain
Analysts have recently increased their price targets for Roivant Sciences. The consensus has moved higher by several dollars per share as positive Phase 3 results for brepocitinib and progress in litigation bolster confidence in the company's outlook.Narratiefupdate • Oct 03
Late-stage Trials For Brepocitinib And Batoclimab Will Unlock Potential, But Execution Risks Remain
The analyst consensus price target for Roivant Sciences has increased from $18.30 to $20.05. Analysts cite strong Phase 3 dermatomyositis data and anticipated commercial potential as key drivers for the upward revision.Narratiefupdate • Sep 18
Late-stage Trials For Brepocitinib And Batoclimab Will Unlock Potential, But Execution Risks Remain
Analysts have raised Roivant Sciences’ price target from $17.00 to $18.30, citing bullish expectations for favorable Phase 3 brepocitinib data in dermatomyositis as a key catalyst and reflecting increased optimism around near-term pipeline milestones. Analyst Commentary Bullish analysts expect favorable risk/reward ahead of brepocitinib Phase 3 data in dermatomyositis, with key results anticipated in September.Seeking Alpha • Apr 23
Roivant Sciences: Primed For Growth With A De-Risked Pipeline
Summary Roivant Sciences has strengthened its financial position through strategic divestitures, boasting $5.2 billion in cash and assets, enabling robust funding for its late-stage pipeline. The company's FcRn inhibitor platform, led by IMVT-1402, shows promise in autoimmune diseases, with positive clinical readouts validating its potential. Priovant's brepocitinib, targeting TYK2/JAK1 pathways, is advancing in Phase 3 trials for Dermatomyositis and Non-Infectious Uveitis, addressing significant unmet needs. Current market valuations significantly undervalue Roivant's potential peak sales, suggesting substantial upside potential given its strong cash position and de-risked late-stage pipeline. Read the full article on Seeking AlphaSeeking Alpha • Feb 05
Roivant: Telavant-Like Success Will Be Challenging To Replicate (Rating Downgrade)
Summary Roivant's $7.1B Telavant sale to Roche demonstrated potential, but the company's stock has underperformed, trading flat while S&P 500 gained 19% since April. Brepocitinib shows promise for NIU treatment with Phase 2 success, but faces challenges including safety concerns and competition from Humira in the $1.5B market. Mosliciguat, targeting PH-ILD, could compete with Tyvaso ($433.8M in Q3 sales) through once-daily dosing and novel mechanism, pending Phase 2 results. Company maintains strong financials with $5.4B in cash/investments and 6-year runway at current burn rate of $76M monthly. I am downgrading to "hold" given the unclear path to profitability and challenges in differentiating clinical assets, though I still see value in a barbell portfolio. Read the full article on Seeking Alpha
Nieuw narratief • Jan 26
Late-stage Trials For Brepocitinib And Batoclimab Will Unlock Potential, But Execution Risks Remain
Successful clinical trials and strategic deals may improve revenue and net margins by focusing on high-value areas.Seeking Alpha • Dec 04
Roivant Sciences: A Biotech Growth Play With Major Ambitions
Summary Roivant Sciences leverages its "Vant" model to develop and monetize drug candidates through subsidiaries, ensuring rapid advancement in therapeutic pipelines. Late-stage assets like Brepocitinib, IMVT-1402, and Mosliciguat position Roivant for significant clinical and commercial milestones by 2025. Strategic divestitures, like Dermavant's sale to Organon for $1.2 billion, support shareholder value through share buybacks and bolster financial stability. ROIV has legal risks from ongoing LNP technology lawsuits, but favorable outcomes could significantly improve its long-term outlook as well. Despite its clinical, legal, and cash burn risks, Roivant's diversified late-stage pipeline and robust financials promise significant growth potential. Read the full article on Seeking AlphaSeeking Alpha • Oct 22
Roivant Sciences: Good Value, But Near-Term Catalysts Could Bring Volatility
Summary Roivant's high valuation stems from its strong cash position, promising drug pipeline, Techbio assets, and strategic partnerships, making it a compelling buy. Recent sales of Telavant and Dermavant have bolstered Roivant's cash reserves. Key potential catalysts include Immunovant’s batoclimab in Phase 3 trials and namilumab in a Phase 2 trial, though drug candidate performance remains a critical risk factor. Litigation against Moderna and Pfizer, coupled with Techbio advancements, could drive future valuation. Read the full article on Seeking AlphaRendement voor aandeelhouders
| ROIV | US Biotechs | US Markt | |
|---|---|---|---|
| 7D | 3.1% | 4.1% | 1.6% |
| 1Y | 219.7% | 41.1% | 18.6% |
Rendement versus industrie: ROIV overtrof de US Biotechs industrie, die het afgelopen jaar een rendement 41.1 % opleverde.
Rendement versus markt: ROIV overtrof de US markt, die het afgelopen jaar een rendement opleverde van 18.6 %.
Prijsvolatiliteit
| ROIV volatility | |
|---|---|
| ROIV Average Weekly Movement | 6.2% |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Stabiele aandelenkoers: ROIV heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 6% ) van ROIV is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2014 | 721 | Matt Gline | roivant.com |
Roivant Sciences Ltd., een biofarmaceutisch bedrijf in een klinische fase, richt zich op het ontdekken, ontwikkelen en commercialiseren van geneesmiddelen en technologieën. De klinische productkandidaten omvatten IMVT-1402, een volledig humaan monoklonaal antilichaam gericht tegen FcRn, in ontwikkeling voor verschillende IgG-gemedieerde auto-immuunindicaties; mosliciguat, een geïnhaleerde sGC-activator in ontwikkeling voor pulmonale hypertensie geassocieerd met interstitiële longziekte; neonatale fragmentkristalliseerbare receptor voor de behandeling van de ziekte van graves, moeilijk te behandelen reumatoïde artritis, de ziekte van sjögren, myasthenia gravis, chronische inflammatoire demyeliniserende polyneuropathie en cutane lupus erythematosus; batoclimab, een volledig humaan monoklonaal antilichaam voor de behandeling van schildklieraandoeningen van het oog; en brepocitinib, een krachtige kleine molecule remmer van TYK2 en JAK1 in ontwikkeling voor de behandeling van dermatomyositis, niet-infectieuze uveïtis, cutane sarcoïdose en andere immuungemedieerde ziekten. Het hoofdprogramma van het bedrijf bestaat uit mosliciguat, een geïnhaleerde sGC activator voor de behandeling van pulmonale hypertensie geassocieerd met interstitiële longaandoeningen en andere cardiopulmonale aandoeningen.
Roivant Sciences Ltd. Samenvatting
| ROIV fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$25.27b |
| Inkomsten(TTM) | -US$299.77m |
| Inkomsten(TTM) | US$8.26m |
3,059x
P/S-verhouding-84.3x
Koers/WinstverhoudingIs ROIV overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| ROIV resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$8.26m |
| Kosten van inkomsten | US$682.20m |
| Brutowinst | -US$673.94m |
| Overige uitgaven | -US$374.17m |
| Inkomsten | -US$299.77m |
Laatst gerapporteerde inkomsten
Mar 31, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -0.42 |
| Brutomarge | -8,159.04% |
| Nettowinstmarge | -3,629.19% |
| Schuld/Eigen Vermogen Verhouding | 0% |
Hoe presteerde ROIV op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/07/05 09:37 |
| Aandelenkoers aan het einde van de dag | 2026/07/02 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2026/03/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Roivant Sciences Ltd. wordt gevolgd door 17 analisten. 11 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| William Pickering | Bernstein |
| Chi Meng Fong | BofA Global Research |
| Prakhar Agrawal | Cantor Fitzgerald & Co. |